CNSDose

About:

CNSDose provides gene testing service and guides for the proper antidepressant.

Twitter/X: cnsdose

Top Investors: Melbourne Accelerator Program

Description:

The CNSDose Report - powered by DNA - guides which antidepressant and dose is most appropriate. With world-first understanding of how antidepressants reach the brain, and backed by clinical trial evidence, CNSDose is the first 2nd generation pharmacogenetic report.

Total Funding Amount:

$1M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Melbourne, Victoria, Australia

Founded Date:

2015-01-01

Contact Email:

info(AT)cnsdose.com

Founders:

Ajeet B Singh

Number of Employees:

1-10

Last Funding Date:

2016-07-12

IPO Status:

Private

Industries: